"We are excited to investigate CUDC-427 monotherapy using a continuous daily dosing regimen, which we believe has the potential to further enhance its anti-tumor activity as a single agent in difficult to treat cancers," said Ali Fattaey, Curis President and Chief Operating Officer. "Additionally, the expansion phase of this trial will further study CUDC-427's activity in patients with ovarian and fallopian tube cancers, where we expect to investigate CUDC-427 in patients with cancers of different genetic profiles, including patients with known gene mutations."In addition to this Phase 1 trial, Curis is also planning to initiate clinical studies with CUDC-427 in patients with breast cancer and other malignancies. Curis is currently planning to initiate a clinical study evaluating the use of CUDC-427 in combination with capecitabine to treat HER2-negative breast cancer patients in 2013. The trial will be designed to initially determine the optimal dose of CUDC-427 in combination with the standard capecitabine regimen. In addition, the company also plans to examine CUDC-427 for the treatment of aggressive lymphomas as well as certain indolent lymphomas such as MALT lymphomas.
Curis Announces Initiation Of A Clinical Trial Of CUDC-427 In Advanced Malignancies
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts